Epim Ab Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., As Chief Medical Officer
06/08/23, 1:00 AM
Location
shanghaiIndustry
e commerce
Position
chief medical officer
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer . As CMO, Dr. Zhu will be responsible for overseeing all clinical development activities for the company’s clinical stage assets
Company Info
Location
shanghai, shanghai, china
Additional Info
EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships.
EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.